Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease

Manuela Pilleri, Angelo Antonini

Research output: Contribution to journalArticle

Abstract

Introduction: Chronic treatment with levodopa is associated with the development of motor fluctuations and dyskinesias particularly in young Parkinson patients. In some cases, dyskinesias become so severe that they interfere with normal movement and negatively impact quality of life. Areas covered: In this review, we discuss benefits and limits of available therapeutic approaches aimed at delaying or managing dyskinesias as well as new strategies that are currently under investigation. Expert opinion: Among available treatments, monotherapy with dopamine agonists in the early phases of the disease reduces the risk for dyskinesias compared with levodopa. Nevertheless, dopamine agonists are unable to prevent dyskinesias once levodopa is added, which is always required once disease severity progresses. Convincing evidence of dyskinesia improvement has been shown only for deep brain stimulation and to some extent also for duodenal levodopa infusion and subcutaneous apomorphine. These approaches are expensive, have restrictive inclusion criteria and can cause potentially serious side effects. Alternative therapies include drugs targeting nondopaminergic neurotransmitter systems. Amantadine improves dyskinesias but its long-term effect is often unsatisfactory. Glutamatergic and gabaergic compounds have been tested in clinical trials, with promising results. By contrast, adrenergic drugs, fipamezole and idazoxan, did not show antidyskinetic effect.

Original languageEnglish
Pages (from-to)281-294
Number of pages14
JournalExpert Opinion on Drug Safety
Volume14
Issue number2
DOIs
Publication statusPublished - Feb 1 2015

Fingerprint

Dyskinesias
Parkinson Disease
Levodopa
Dopamine Agonists
Therapeutics
Idazoxan
Amantadine
Subcutaneous Infusions
Deep Brain Stimulation
Apomorphine
Expert Testimony
Drug Delivery Systems
Complementary Therapies
Adrenergic Agents
Neurotransmitter Agents
Quality of Life
Clinical Trials

Keywords

  • Dyskinesias
  • Motor complications
  • Parkinson's disease
  • Therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease. / Pilleri, Manuela; Antonini, Angelo.

In: Expert Opinion on Drug Safety, Vol. 14, No. 2, 01.02.2015, p. 281-294.

Research output: Contribution to journalArticle

Pilleri, Manuela ; Antonini, Angelo. / Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease. In: Expert Opinion on Drug Safety. 2015 ; Vol. 14, No. 2. pp. 281-294.
@article{177c60850f254a2580d36b9f6122a115,
title = "Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease",
abstract = "Introduction: Chronic treatment with levodopa is associated with the development of motor fluctuations and dyskinesias particularly in young Parkinson patients. In some cases, dyskinesias become so severe that they interfere with normal movement and negatively impact quality of life. Areas covered: In this review, we discuss benefits and limits of available therapeutic approaches aimed at delaying or managing dyskinesias as well as new strategies that are currently under investigation. Expert opinion: Among available treatments, monotherapy with dopamine agonists in the early phases of the disease reduces the risk for dyskinesias compared with levodopa. Nevertheless, dopamine agonists are unable to prevent dyskinesias once levodopa is added, which is always required once disease severity progresses. Convincing evidence of dyskinesia improvement has been shown only for deep brain stimulation and to some extent also for duodenal levodopa infusion and subcutaneous apomorphine. These approaches are expensive, have restrictive inclusion criteria and can cause potentially serious side effects. Alternative therapies include drugs targeting nondopaminergic neurotransmitter systems. Amantadine improves dyskinesias but its long-term effect is often unsatisfactory. Glutamatergic and gabaergic compounds have been tested in clinical trials, with promising results. By contrast, adrenergic drugs, fipamezole and idazoxan, did not show antidyskinetic effect.",
keywords = "Dyskinesias, Motor complications, Parkinson's disease, Therapy",
author = "Manuela Pilleri and Angelo Antonini",
year = "2015",
month = "2",
day = "1",
doi = "10.1517/14740338.2015.988137",
language = "English",
volume = "14",
pages = "281--294",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease

AU - Pilleri, Manuela

AU - Antonini, Angelo

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Introduction: Chronic treatment with levodopa is associated with the development of motor fluctuations and dyskinesias particularly in young Parkinson patients. In some cases, dyskinesias become so severe that they interfere with normal movement and negatively impact quality of life. Areas covered: In this review, we discuss benefits and limits of available therapeutic approaches aimed at delaying or managing dyskinesias as well as new strategies that are currently under investigation. Expert opinion: Among available treatments, monotherapy with dopamine agonists in the early phases of the disease reduces the risk for dyskinesias compared with levodopa. Nevertheless, dopamine agonists are unable to prevent dyskinesias once levodopa is added, which is always required once disease severity progresses. Convincing evidence of dyskinesia improvement has been shown only for deep brain stimulation and to some extent also for duodenal levodopa infusion and subcutaneous apomorphine. These approaches are expensive, have restrictive inclusion criteria and can cause potentially serious side effects. Alternative therapies include drugs targeting nondopaminergic neurotransmitter systems. Amantadine improves dyskinesias but its long-term effect is often unsatisfactory. Glutamatergic and gabaergic compounds have been tested in clinical trials, with promising results. By contrast, adrenergic drugs, fipamezole and idazoxan, did not show antidyskinetic effect.

AB - Introduction: Chronic treatment with levodopa is associated with the development of motor fluctuations and dyskinesias particularly in young Parkinson patients. In some cases, dyskinesias become so severe that they interfere with normal movement and negatively impact quality of life. Areas covered: In this review, we discuss benefits and limits of available therapeutic approaches aimed at delaying or managing dyskinesias as well as new strategies that are currently under investigation. Expert opinion: Among available treatments, monotherapy with dopamine agonists in the early phases of the disease reduces the risk for dyskinesias compared with levodopa. Nevertheless, dopamine agonists are unable to prevent dyskinesias once levodopa is added, which is always required once disease severity progresses. Convincing evidence of dyskinesia improvement has been shown only for deep brain stimulation and to some extent also for duodenal levodopa infusion and subcutaneous apomorphine. These approaches are expensive, have restrictive inclusion criteria and can cause potentially serious side effects. Alternative therapies include drugs targeting nondopaminergic neurotransmitter systems. Amantadine improves dyskinesias but its long-term effect is often unsatisfactory. Glutamatergic and gabaergic compounds have been tested in clinical trials, with promising results. By contrast, adrenergic drugs, fipamezole and idazoxan, did not show antidyskinetic effect.

KW - Dyskinesias

KW - Motor complications

KW - Parkinson's disease

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84921395842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921395842&partnerID=8YFLogxK

U2 - 10.1517/14740338.2015.988137

DO - 10.1517/14740338.2015.988137

M3 - Article

C2 - 25483147

AN - SCOPUS:84921395842

VL - 14

SP - 281

EP - 294

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 2

ER -